A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer
Crossref DOI link: https://doi.org/10.1186/s12920-020-0682-5
Published Online: 2020-04-03
Published Print: 2020-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhang, Xiaoli
Klamer, Brett
Li, Jin
Fernandez, Soledad
Li, Lang
Text and Data Mining valid from 2020-04-01
Version of Record valid from 2020-04-03
Article History
First Online: 3 April 2020
Ethics approval and consent to participate
: Not applicable.
: The authors declare that they have no competing interests.